Key Points
- Haemonetics CAO Farris Maryanne Maunsell sold 836 shares for about $101,148, reducing her position by 12.55%; she retained 5,828 shares after the transaction.
- The company beat quarterly expectations, reporting $1.35 in adjusted EPS and $357.76 million in revenue, with revenue up 9.4% year over year.
- Analysts’ consensus rating was “Moderate Buy,” with an average price target of $129; shares traded at $123.16 in Friday midday trading.
Haemonetics Corporation (NYSE:HAE - Get Free Report) CAO Farris Maryanne Maunsell sold 836 shares of the stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $120.99, for a total transaction of $101,147.64. Following the transaction, the chief accounting officer owned 5,828 shares of the company's stock, valued at $705,129.72. The trade was a 12.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Haemonetics Stock Up 0.4%
HAE stock traded up $0.45 during midday trading on Friday, hitting $123.16. The company's stock had a trading volume of 439,677 shares, compared to its average volume of 686,811. The company has a debt-to-equity ratio of 1.24, a current ratio of 2.84 and a quick ratio of 1.83. Haemonetics Corporation has a twelve month low of $51.00 and a twelve month high of $132.00. The company's fifty day moving average price is $113.34 and its 200 day moving average price is $81.36. The stock has a market capitalization of $5.61 billion, a P/E ratio of 55.23, a PEG ratio of 2.45 and a beta of 0.63.
Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $1.35 EPS for the quarter, topping the consensus estimate of $1.29 by $0.06. Haemonetics had a net margin of 7.52% and a return on equity of 27.42%. The firm had revenue of $357.76 million for the quarter, compared to analysts' expectations of $345.15 million. During the same period in the previous year, the firm posted $1.27 EPS. The company's revenue for the quarter was up 9.4% on a year-over-year basis. As a group, equities research analysts predict that Haemonetics Corporation will post 5.32 EPS for the current year.
Hedge Funds Weigh In On Haemonetics
Hedge funds and other institutional investors have recently bought and sold shares of the business. Bessemer Group Inc. grew its holdings in Haemonetics by 53.7% during the third quarter. Bessemer Group Inc. now owns 269 shares of the medical instruments supplier's stock worth $28,000 after purchasing an additional 94 shares during the period. Fortitude Family Office LLC boosted its stake in shares of Haemonetics by 104.5% during the 3rd quarter. Fortitude Family Office LLC now owns 272 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 139 shares during the period. Root Financial Partners LLC acquired a new position in shares of Haemonetics during the 3rd quarter worth approximately $40,000. Kelleher Financial Advisors acquired a new position in shares of Haemonetics during the 2nd quarter worth approximately $38,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new position in shares of Haemonetics during the 2nd quarter worth approximately $44,000. Institutional investors own 99.67% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research firms recently issued reports on HAE. Mizuho set a $165.00 target price on Haemonetics in a research report on Thursday, November 5th. BTIG Research increased their price target on Haemonetics from $130.00 to $142.00 and gave the company a "buy" rating in a research report on Thursday, November 5th. Raymond James Financial increased their price target on Haemonetics from $105.00 to $125.00 and gave the company an "outperform" rating in a research report on Thursday, September 3rd. Barrington Research raised their price target on Haemonetics from $140.00 to $145.00 and gave the company an "outperform" rating in a research note on Friday, November 6th. Finally, Jefferies Financial Group initiated coverage on Haemonetics in a research report on Friday. They set a "buy" rating and a $150.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Haemonetics currently has an average rating of "Moderate Buy" and an average price target of $129.00.
View Our Latest Stock Analysis on Haemonetics
Haemonetics Company Profile
(
Get Free Report)
Haemonetics Corporation is a global medical technology company focused on blood and plasma collection, processing and management. Its products and services are used by plasma collection organizations, blood centers and hospitals. The company provides automated plasma collection systems and related software and supplies, as well as technologies for collecting and processing blood components. Its hospital offerings include devices for surgical blood salvage and tools that help clinicians assess blood clotting and guide transfusion decisions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
